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Abstract
Background: This study aimed to evaluate the role of b-blocker therapy on modulating interleukin 
(IL)-33/ST2 (interleukin-1 receptor-like 1) signaling during ventricular remodeling related to heart 
failure (HF) after acute myocardial infarction (AMI).
Methods: Sprague-Dawley rats that survived surgery to induce AMI were randomly divided into the 
placebo group and the b-blocker treatment group. A sham group was used as a control. Left ventricular 
(LV) function variables, the myocardial infarct size, fibrosis and IL-33/ST2 protein expression was 
measured.
Results: Compared with the placebo group, b-blocker treatment significantly improved LV function 
and reduced infarct size (p < 0.05). There was higher protein expression of IL-33 (p < 0.05) and sST2  
(p < 0.05), as well as higher expression of fibrosis (p < 0.05), compared to the sham group. Notably, the 
high expression of cardioprotective IL-33 was not affected by b-blocker treatment (p > 0.05), however, 
treatment with b-blocker enhanced IL-33/ST2 signaling, with lower expression of sST2 (p < 0.05) and 
significantly attenuated fibrosis (p < 0.05).
Conclusions: Our study suggested that b-blocker therapy might play a beneficial role in the modula-
tion of IL-33/ST2 signaling during ventricular remodeling. These results may be helpful in identifying  
IL-33/ST2 systems as putative b-blocker targets at an early stage after AMI. (Cardiol J 2017; 24, 2: 188–194)
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Introduction
Heart failure (HF) and acute myocardial in-
farction (AMI) are the most common causes of 
morbidity and mortality worldwide [1]. The loss of 
cardiac function after AMI drives specific cardiac 
remodeling and hypertrophy processes in order to 
preserve cardiac output, however, cardiac remod-
eling and hypertrophy processes lead to further 
deterioration in cardiac function [2]. During the 
past several decades, a large body of evidence has 
suggested that b-blocker therapy can reduce HF-
-related morbidity and mortality [3]. While these 
studies have shown that b-blockers can improve 
left ventricular (LV) remodeling [4], the protective 
mechanisms are not well understood.
ST2 is an interleukin-1 (IL-1) receptor family 
member with both soluble (sST2) and transmem-
brane (ST2L) isoforms. Myocardial fibrosis and 
hypertrophy are attenuated through the interaction 
between IL-33 and ST2L [5–8]. The role of sST2 
in remodeling seems to be mediated by its effect 
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on its primary ligand, IL-33, which itself is also 
synthesized when cardiac fibroblasts are mechani-
cally stretched. IL-33 has been shown to inhibit 
cardiomyocyte hypertrophy, fibrosis, and apoptosis. 
In contrast, sST2 acts as a decoy receptor that 
neutralizes IL-33. In addition, sST2 impairs the 
cardioprotective role of the IL-33/ST2L signaling 
pathway, resulting in cardiac hypertrophy and fibro-
sis. Several studies have shown that sST2 levels 
can significantly predict LV remodeling and can 
strongly predict the adverse outcomes in patients 
with HF [9]. Therefore, sST2 may be a promising 
prognostic biomarker in patients with established 
HF after AMI.
Given the relationship between sST2 and HF, 
we hypothesized that an intersection between 
b-blocker therapy and the IL-33/ST2L signaling 
pathway may exist. The current study aimed to 
evaluate the role of b-blocker therapy in modulating 
IL-33/ST2 signaling during ventricular remodeling 
related to HF after AMI.
Methods
Study protocol
The current study followed the Guide for the 
Use and Care of Laboratory Animals published by 
the United States National Institutes of Health. 
The research was approved by the Animal Research 
Councils and the Ethics Council, Health Center, 
Xuanwu Hospital, Capital Medical University, 
China.
Fifty healthy male pathogen-free Sprague-
Dawley rats (280 ± 30 g) from the Experimental 
Animal Center of Xuanwu Hospital, Capital Medical 
University were used in this study. The AMI model 
was established by occlusion of the left anterior 
descending artery in 42 rats, as described previ-
ously [10]. At the same time point, according to 
two previous studies [11, 12], we estimated that 
a sample of 8 rats in the sham group was appropri-
ate when considering cost and ethics. The 8 rats 
received the same operation without ligation of 
the left anterior descending coronary artery. Anes-
thesia was induced by an intraperitoneal injection 
of pentobarbital sodium solution (2%). The rats 
were ventilated mechanically (oxygen, 1 L/min). 
Twenty-four hours later, only 30 rats with AMI 
had survived, but all 8 sham rats had survived. The 
30 rats with AMI were randomized in a 1:1 ratio 
into the placebo group and the b-blocker treat-
ment group as follows: (1) The placebo group, the 
AMI rats receiving water by gavage (n = 15) and 
(2) The b-blocker treatment group, the AMI rats 
receiving bisoprolol (from Merck KGaA, Darm-
stadt, Germany) (n = 15; 10 mg/kg/day in drinking 
water for 4 weeks); (3) In addition, a sham group 
(without AMI) received water by gavage (n = 8). 
After a 4-week study period, echocardiography 
was performed and the respective parameters 
were obtained. Subsequently, the 30 AMI rats and 
the 8 sham rats were euthanized, and the hearts 
were harvested. The myocardial infarct size was 
measured, and western blot assays of the infarcted 
area were performed.
Echocardiographic measurements
Left ventricular function variables were evalu-
ated by using echocardiography in the three groups 
of rats anesthetized with pentobarbital sodium solu-
tion (2%). A Vevo-770 small animal ultrasound (Vis-
ualSonics Inc., Toronto, Canada) with a 17.5-MHz 
probe frequency was used to assess the cardiac 
characteristics in a noninvasive manner. The M-
mode images were taken through the papillary 
muscle level short axis. The thicknesses of the 
LV end-diastolic anterior wall (LVEDAW), LV 
end-diastolic posterior wall (LVEDPW), LV end-
diastolic diameter (LVEDD), and LV end-systolic 
diameter (LVESD) were measured. According 
to the American Standards of Echocardiography, 
the variables of three to five consecutive cardiac 
cycles were observed and measured. The ejection 
fraction (EF) and fractional shortening (FS) were 
calculated according to a previous report [13]. 
All images were analyzed by Vevo-770 software 
(VisualSonics Inc.).
Infarct size
At the end of week 4 (w4), the hearts were 
harvested. Five rats in the b-blocker treatment 
group and 5 rats in the placebo group underwent 
myocardial infarct size measurement by 2, 3, 
5-triphenyltetrazolium chloride (TTC) staining. 
Myocardial infarct size in the sham group was not 
measured. The surgical procedure was based on 
a previous research report [14]. The hearts were 
rapidly excised, atria were removed, and ventri-
cles were sliced transversely into five cross slices 
with uniform thickness. And then the slices were 
stained at 37°C for 30 min with 1% TTC, which 
stains only the viable myocardium. The white 
region indicated an infarcted myocardium (area of 
necrosis, AN), the light red region indicated an is-
chemic myocardium, and the blue region indicated 
a normal myocardium. The ratio of the infarcted area 
and the area at risk (the sum of the ischemic and 
infarcted areas, AAR), which is AN/AAR, was used 
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to represent the extent of the infarction. AAR/LV 
was used to represent the extent of the AAR. AN, 
AAR, and LV were measured by Image-ProPlus 
analysis software (version 4.1; Media Cybernetics, 
Rockville, MD, USA).
Western blot assay of IL-33, sST2,  
Col I, Col III, and TIMP-1
At the end of w4, the AN was collected and 
total protein was extracted as described previously 
[15]. The remaining 10 rats in b-blocker treatment 
and placebo groups and 8 rats in the sham group 
were designated for Western blot assay. The tissue 
for protein extraction in the sham group was from 
the LV anterior wall near the apex. The location 
was similar with that in the control and b-blocker 
treatment groups. The extracted protein (200 μg) 
was added to an 8% SDS-PAGE separating gel and 
transferred to a nitrocellulose membrane (Milli-
pore, Bedford, MA, USA). Following blocking, the 
membrane was incubated at room temperature for 
4 h with one of the following primary antibodies: 
IL-33, sST2, collagen type I (Col I), collagen type III 
(Col III), and tissue inhibitor of metalloproteinase-1 
(TIMP-1) (all diluted 1:500) from Santa Cruz Bio-
technology (Santa Cruz, CA, USA). The antibody-
tagged membranes were probed with a secondary 
antibody solution consisting of either a 1:1,000 
dilution of horseradish peroxidase-conjugated rabbit 
anti-rat IgG (for IL-33, sST2) or a 1:1,000 dilution of 
horseradish peroxidase-conjugated goat anti-rabbit 
IgG (for Col I, Col III, TIMP-1, and glyceraldehyde 
phosphate dehydrogenase (GAPDH) from Promega 
(Madison, WI, USA) for 1 h at room temperature. 
The integrated optical density (mean optical density 
× area) was detected by Image-ProPlus analysis 
software. The ratio of the target protein and GAPDH 
reflected the relative level of the target protein.
Statistical analysis
Continuous variables were presented as mean 
± standard deviation (SD), and differences between 
groups were compared by one-way analysis of 
variance (ANOVA) followed by Student-Newman-
Keuls post hoc analysis. Categorical variables 
between groups were compared by Fisher’s exact 
test. The value of p < 0.05 was considered statis-
tically significant. Statistics were analyzed using 
SPSS software version 19 (SPSS Inc., Chicago, 
IL, USA).
Results
All 8 rats in the sham group survived surgery. 
Four weeks after induction of AMI, 30 rats survived 
and 12 rats died. One rat died during anesthesia, 
7 rats died of ventricular arrhythmia, 1 rat died 
of pneumothorax, and 3 rats died of HF during 
the procedure. The 30 rats that survived were 
randomly divided into the placebo group or the 
b-blocker treatment group.
Echocardiography
At w4 after induction of AMI, the placebo 
group had significantly higher LVEDD and LVESD 
values (p < 0.05 vs. the sham group), as well as 
significantly lower LVEDAW, FS, and EF values 
(p < 0.05 vs. the sham group), however, the placebo 
rats did not differ from the rats in the sham group 
in terms of the LVEDPW thickness (p > 0.05).
Beta-blocker treatment significantly decreased 
the LVEDD and LVESD values (p < 0.05 vs. the 
placebo group) and significantly increased the 
LVEDAW, FS, and EF values (p < 0.05 vs. the pla-
cebo group), however, the LVEDPW thickness did 
not change significantly after b-blocker treatment 
(p > 0.05 vs. the placebo group; Table 1).
Table 1. Effect of b-blocker treatment on echocardiographic data on the cardiac structure and function  
in rats following acute myocardial infarction (n = 15 each for the placebo group and the b-blocker 
treatment group; n = 8 for the sham group).
Parameter Sham group Placebo group Beta-blocker
LV end-diastolic anterior wall [mm] 1.7 ± 0.2 0.5 ± 0.1* 0.8 ± 0.1#
LV end-systolic diameter [mm] 3.3 ± 0.2 4.5 ± 0.3* 4.1 ± 0.2#
LV end-diastolic diameter [mm] 7.1 ± 0.3 9.2 ± 0.4* 8.6 ± 0.3#
LV end-diastolic posterior wall [mm] 1.7 ± 0.1 1.6 ± 0.1 1.6 ± 0.2
Ejection fraction [%] 75.8 ± 4.5 48.5 ± 7.7* 62.8 ± 5.6#
Fractional shortening [%] 49.3 ± 2.7 31.5 ± 3.3* 40.8 ± 3.8#
Continuous variables are presented as mean ± standard deviation. *Significant difference when compared with the sham group. #Significant 
difference when compared with the placebo group; LV — left ventricular
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Infarct size
The placebo group showed an obvious myo-
cardial infarction (AN/AAR, 65.23 ± 6.46%). Com-
pared with the placebo group, the AN/AAR ratio of 
the b-blocker treatment group (AN/AAR, 48.96 ± 
± 6.22%) was significantly lower (p < 0.05). AAR/ 
/LV was similar between the placebo group (41.26 ± 
± 6.12%) and the b-blocker treatment group (40.96 ± 
± 5.92%) (p > 0.05; Fig. 1).
IL-33/ST2 signaling pathway
The IL-33/ST2 signaling pathway was evalu-
ated by analyzing the protein expression of cardio-
protective IL-33 and sST2, as shown in Figure 2. 
In the infarcted myocardium, there was higher 
protein expression of IL-33 (p < 0.05) and sST2 
(p < 0.05), compared to the sham group. Notably, 
the high protein expression of the cardioprotective 
IL-33 was not affected by b-blocker treatment 
(p > 0.05), however, the sST2 levels were signifi-
cantly reduced by b-blocker treatment (p < 0.05).
Fibrosis
Fibrosis was evaluated by analyzing the 
protein expression of Col I, Col III, and TIMP-1. 
As shown in Figure 3, in the infarcted area, 
there was higher expression of Col I, Col III, 
and TIMP-1 in the placebo group (p < 0.05), 
compared to the sham group. Compared to the 
placebo group, b-blocker treatment was associ-
ated with lower expression of Col I, Col III, and 
TIMP-1 (p < 0.05).
Figure 1. A. Comparisons of AN/AAR and AAR/LV be-
tween the placebo and b-blocker treatment groups (n = 5 
per group). The blue bars indicate placebo group and 
the red bars indicate b-blocker treatment group. Vari-
ables are presented as mean ± standard deviation and 
compared by one-way ANOVA. #Significant difference 
compared to the placebo group. The ratio of the in-
farcted area and the area at risk (the sum of the ischemic 
and necrotic areas) (AN/AAR) was used to represent the 
extent of the infarction. AAR/LV was used to represent 
the extent of the AAR; AN — area of necrosis; AAR — 
area at risk; LV — area of left ventricle; B. Staining of the 
myocardium with triphenyltetrazolium chloride. Ventri-
cles were sliced transversely into five cross slices with 
uniform thickness. From right to left: heart base to apex. 
The white region indicates an infarcted myocardium, 
the light red region indicates an ischemic myocardium, 
and the blue region indicates a normal myocardium.
Figure 2. Protein expression of interleukin (IL)-33 and 
sST2 in the three groups; A. Comparisons of IL-33 and 
sST2 among the three groups (10 rats in b-blocker treat-
ment group, 10 in placebo group and 8 in sham group). 
The blue bars indicate sham group, the red bars indi-
cate placebo group and green bars indicate b-blocker 
treatment group. Variables are presented as mean ± 
± standard deviation and compared by one-way ANO-
VA; *Significant difference compared with the sham 
group; #Significant difference compared with the pla-
cebo group; B. Representative images of the protein 
expression of IL-33, sST2, and GAPDH. Note: GAPDH is 
a reference; 1 — sham group; 2 — placebo group; 3 — 
b-blocker treatment group; GAPDH — glyceraldehyde 
phosphate dehydrogenase.
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Discussion
Due to the high prevalence of b-blocker pre-
scriptions in patients with cardiovascular disease, 
there is significant interest in elucidating the 
mechanisms contributing to the clinical benefit 
of b-blocker therapy. Similarly, there have been 
efforts to increase the understanding of the role 
of sST2 in the pharmacology of b-blocker therapy. 
However, the contribution of IL-33/ST2 signaling 
in ventricular remodeling related to HF after AMI 
remains unknown. To the best of our knowledge, 
this is the first study to show an interaction be-
tween b-blocker therapy and IL-33/ST2 signaling. 
Notably, we demonstrated that b-blocker therapy 
modulates IL-33/sST2 signaling and cardiac ven-
tricular remodeling, which correlate with markers 
of fibrosis. This signaling could be responsible for 
the cardioprotective effects of b-blocker therapy 
in AMI patients.
Heart failure is a very complex clinical syn-
drome due to structural or functional impairment 
of ejection of blood and/or ventricular filling [16]. 
Biomarkers are indispensable tools for diagnosis 
and prognostication in many kinds of cardiovascu-
lar diseases, and some have become standard of 
care [17]. Soluble ST2 is a novel biomarker that 
reflects inflammation, fibrosis, and cardiac stress, 
which is correlated with the pathophysiology 
of adverse myocardial remodeling and HF [18]. 
ST2 measurements in patients with either acute 
or chronic HF are now strongly recommended 
for additive risk stratification, according to the 
2013 American College of Cardiology Foundation 
and American Heart Association joint guidelines 
[19]. However, the expected benefits of b-blocker 
therapy in those with elevated concentrations of 
sST2 have been elusive. The recent PROTECT 
study has shown that chronic systolic HF patients 
with lower ST2 levels are likely to get the most 
benefit from higher b-blocker doses [20]. While this 
report is encouraging, the putative link between 
ST2 and the cardioprotective effect of b-blocker 
therapy requires further clarification.
One of the critical factors in cardiac remodeling 
is excessive activation of the sympathetic nervous 
system. It contributes to the progression of HF 
through remodeling, thus providing a biomechani-
cal explanation for the use of medications to inhibit 
these pathways to deter the progression of HF 
through inhibiting adverse remodeling [21, 22]. 
Over the past decade, several randomized clinical 
trials have shown that administration of b-blockers 
improves LV function and reduces morbidity and 
mortality in patients with both acute and chronic 
HF [23–26].
In the present study, we used an animal model 
of AMI to evaluate myocardial expression of IL-33 
and sST2 at w4 after b-blocker therapy. We found 
that compared with the sham group, the placebo 
group had significantly decreased LV function as 
shown by the higher LVESD and LVEDD values, as 
well as the lower LVEDAW, FS, and EF values. In 
the infarcted myocardium, compared with the sham 
group, the placebo group featured higher concen-
trations of IL-33 and sST2, as well as higher con-
centrations of Col I, Col III, and TIMP-1. The up-
regulation of IL-33 supports its participation in the 
protective response in the infarcted myocardium. 
Figure 3. Protein expression of collagen type I (Col I), 
collagen type III (Col III), and tissue inhibitor of metal-
loproteinase (TIMP)-1 in the three groups; A. Compari-
sons of Col I, Col III, and TIMP-1 among the three groups 
(10 rats in b-blocker treatment group, 10 in placebo 
group and 8 in sham group). The blue bars indicate 
sham group, the red bars indicate placebo group and 
green bars indicate b-blocker treatment group. Vari-
ables are presented as mean ± standard deviation and 
compared by one-way ANOVA; *Significant difference 
compared with the sham group; #Significant difference 
compared with the placebo group; B. Representative 
images of the protein expression of Col I, Col III, TIMP-1, 
and GAPDH; Note: GAPDH is a reference; 1 — sham 
group; 2 — placebo group; 3 — b-blocker treatment 
group; GAPDH — glyceraldehyde phosphate dehydro-
genase.
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IL-33 has been shown to inhibit cardiomyocyte 
hypertrophy, fibrosis, and apoptosis. The upregula-
tion of sST2 supports the assumption that it acts 
as a decoy receptor that neutralizes IL-33 and 
impairs the cardioprotective role. The upregulation 
of IL-33 and sST2 correlates with cardiac markers 
of fibrosis in the setting of early remodeling after 
AMI and provides a plausible explanation for their 
measurable elevation. The effects on LV function 
and fibrosis in the placebo group and the effects on 
the IL-33/sST2 pathway are similar to the results 
reported previously [12]. Sanchez-Mas et al. [12] 
have reported that AMI upregulates the mRNA 
expression of sST2 and IL-33 in the infarcted 
myocardium and that the level of sST2 positively 
correlates with cardiac markers of fibrosis dur-
ing the first week following AMI. In addition, the 
expression of sST2 is rapidly upregulated during 
the first 4 weeks, with levels correlating to the 
ongoing process of fibrosis. Moreover, Lax et al. 
[11] have reported that in the infarcted myocar-
dium, compared with sham animals, the placebo 
group had higher concentrations of IL-33, sST2, 
and fibrosis markers.
We found that b-blocker therapy significantly 
decreased myocardial infarct size ratio compared 
with the placebo group. However, the area at risk 
ratio was similar between the b-blocker therapy 
and placebo groups. These data suggest that the 
ligation location of the left anterior descending 
artery was similar between b-blocker therapy 
treatment group and the placebo group in our study.
We also found that b-blocker therapy signifi-
cantly improved LV function, reduced the infarct 
size, enhanced IL-33/ST2 signaling with lower 
expression of sST2, and attenuated the levels of 
Col I, Col III, and TIMP-1, compared with the pla-
cebo group. Notably, b-blocker therapy decreased 
the expression of sST2 and did not affect the up-
regulated level of IL-33. It supports the suggested 
protective role of IL-33 in response to AMI. Such 
a finding would suggest an overall protective en-
hancement of IL-33/ST2L signaling. On the whole, 
our findings would be helpful in identifying IL-33/ 
/ST2 systems as putative b-blocker targets at an 
early stage after AMI.
Conclusions
In conclusion, our results are novel and 
substantially extend the understanding of how 
b-blocker therapy modulates IL-33/ST2 signaling 
during ventricular remodeling related to HF after 
AMI. Some limitations of the present study include 
the following: (1) There was insufficient selection 
of cardiac remodeling markers and evaluation of 
the injured myocardium. Therefore, assessment 
of additional cardiac remodeling markers, such 
as inflammatory markers and apoptosis markers 
could have added additional value to the current 
study. (2) The relationship between IL-33/ST2 
and b-blocker therapy could have been analyzed 
using a correlation analysis. (3) Additional in vitro 
assays could have supplemented the in vivo study 
to explore the direct actions of b-blocker therapy 
in cardiomyocytes. We will focus on these limita-
tions in our future studies. However, our present 
findings suggest that b-blocker therapy might play 
a beneficial role in the regulation of IL-33/ST2 
signaling during ventricular remodeling related to 
HF after AMI. Our study implies that the beneficial 
actions of b-blocker therapy on ventricular remod-
eling related to HF after AMI could be mediated 
by enhanced IL-33/ST2 signaling.
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